PF-00489791
Unknown / undisclosed
Evidence outlook · program status
Discontinued, for reasons the sponsor has not stated
PF-00489791 was Pfizer’s PDE5 inhibitor. Its registered studies were in Raynaud’s phenomenon, diabetic nephropathy, pulmonary arterial hypertension, high blood pressure and post-herpetic neuralgia, plus a healthy-volunteer study. Pfizer’s own text on the terminated study NCT00853112 attributes the stop to a change in the compound’s development rather than to safety. The programme itself then ended: PF-00489791 is listed under Cardiovascular/Metabolics in the Pfizer pipeline filed with the SEC on 28 April 2014 (exhibit 99.6 to Pfizer’s 8-K, accession 0001193125-14-161303), no SEC filing has named it since May 2014, and Pfizer’s current pipeline page (pfizer.com/science/drug-product-pipeline, updated 4 August 2026) enumerates every investigational medicine by phase and therapy area without it. No reason for the programme stop is stated. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01090492 NCT01090492 · Raynaud's Disease, Peripheral Vascular Disease The study randomized 243 participants to double-blind PF-00489791 or matching placebo in a crossover design, using the patient-reported Raynaud's Condition Score as its primary clinical endpoint. Results were mixed: the 20 mg dose significantly improved the score in primary Raynaud's (p=0.0057), but the other primary comparisons were not statistically significant, so the evidence supports a moderate grade. Registry: NCT01090492 | 2 | Change From Baseline in Mean Raynaud's Condition Score (RCS) at Week 4 (Baseline, Week 4) 2011-05-31 | Change From Baseline in Mean Raynaud's Condition Score (RCS) at Week 4 (Baseline, Week 4): PF-00489791 4 mg (PRP) — Baseline: 3.04 units on a scale (Standard Deviation 1.899); Change at Week 4: -0.76 units on a scale (Standard Deviation 1.901) | PF-00489791 20 mg (PRP) — Baseline: 2.9 units on a scale (Standard Deviation 2.16); Change at Week 4: -1.05 units on a scale (Standard Deviation 1.771) | PF-00489791 4 mg (SRP) — Baseline: 3.14 units on a scale (Standard Deviation 2.431); Change at Week 4: -0.82 units on a scale (Standard Deviation 1.624) | PF-00489791 20 mg (SRP) — Baseline: 2.53 units on a scale (Standard Deviation 1.833); Change at Week 4: -0.15 units on a scale (Standard Deviation 1.09) vs Placebo (PRP) — Baseline: 2.98 units on a scale (Standard Deviation 1.958); Change at Week 4: -0.61 units on a scale (Standard Deviation 1.404) | Placebo (SRP) — Baseline: 2.97 units on a scale (Standard Deviation 2.492); Change at Week 4: -0.24 units on a scale (Standard Deviation 1.437) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.